ClinicalTrials.gg
Status unknownNCT02356432CMB-NOWUpdated Oct 20, 2016

Cerebral Microbleeds During NOACs or Warfarin Therapy in NVAF Patients With Acute Ischemic Stroke (CMB-NOW)

An observational study in Ischemic Stroke and Atrial Fibrillation Symptomatic, sponsored by Tokai University. Status unknown at 3 sites in Japan. Open to participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2016-10-20.

Sponsored by Tokai University · Observational

How we know

The sponsor has not verified this record recently (last verified Oct 2016), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
86
Ages
20 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Ischemic Stroke with a site in Japan — 7 open to participants now, 11 under way, 3 of them phase 3. Ischemic Stroke · Japan.

Started
2015
with 1 other
Observational
8 of 43
1 open now
Registered
14th of 43
by date

Among the 43 studies in Ischemic Stroke with a site in Japan, this one is one of 2 that started in 2015, is one of 8 observational ones, and was the 14th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

7 of the 43 studies in Ischemic Stroke with a site in Japan are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 20 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Ischemic Stroke with a site in Japan, or all of them as a file.
02

Study summary

Anticoagulants are generally recognized as a necessary therapy to prevent the recurrence of ischemic stroke in patients with non-valvular atrial fibrillation (NVAF), but in some patients they also cause bleedings, particularly intracranial hemorrhage. One of the independent predictors of intracerebral hemorrhage is the presence of cerebral microbleeds (CMBs); a high incidence of intracerebral hemorrhage is reported in patients with multiple CMBs. Recent study suggested that patients who had CMBs at baseline developed more new CMBs after 2 years (26%), compared with patients (12%) who did not have CMBs at baseline. However, there has been no study on the progression of CMBs in patients receiving so-called novel oral anticoagulants (NOACs).

This study tests the hypothesis that the incidence of hemorrhagic stroke is lower in patients receiving NOACs (dabigatran, rivaroxaban, apixaban, and edoxaban) than in those receiving warfarin, and this difference reflects the difference in the effects of warfarin and NOACs on the progression of CMBs. Towards this goal, we enroll 200 patients with at least one CMB detected by 1.5 T MRI (T2*WI) at baseline, who treated with NOACs or warfarin for 12 months. Primary endpoint is the proportion of subjects with an increased number of CMBs at Month 12 of treatment with NOACs or warfarin. If the results of this study support the efficacy of NOACs in preventing increase of CMBs, this would be of great interest to domestic and overseas clinicians, in view of the potential therapeutic impact, including that for primary prevention of ischemic stroke.

Read the detailed description
  1. Introduction Anticoagulants are generally recognized as a necessary therapy to prevent the recurrence of ischemic stroke in patients with non-valvular atrial fibrillation (NVAF), but in some patients they also cause bleedings, particularly intracranial hemorrhage (including intracerebral hemorrhage). One of the independent predictors of intracerebral hemorrhage is the presence of cerebral microbleeds (CMBs); a high incidence of intracerebral hemorrhage is reported in patients with multiple CMBs (Soo et al, J Neurol, 2008; Lee et al, Neurology, 2009) Also, the rate and absolute number of CMBs increase in proportion to CHADS2 score in patients with cerebral infarction accompanying NVAF (Song et al, Eur J Neurol, 2013). Among CMB-positive patients, a high incidence of intracranial hemorrhage associated with oral anticoagulation therapy has been reported (Song et al, Eur J Neurol, 2013); suggesting a relationship between the occurrence or absolute number of CMBs and the development of intracranial hemorrhage during oral anticoagulation therapy. Imaizumi et al. (J Stroke Cerebrovasc Dis, 2013) found that warfarin alone did not increase the incidence of intracerebral hemorrhage in all subjects with CMBs, but subjects with 3 or more deep CMBs did show an increased incidence. Also, a meta-analysis conducted by Lovelock et al. (Stroke, 2010) demonstrated a higher incidence of CMBs in patients with intracerebral hemorrhage receiving warfarin than in patients with intracerebral hemorrhage not receiving antithrombotic therapy. Recently, Orken et al (Clin Neurol Neurosurg, 2013) suggested that patients who had CMBs at baseline developed more new CMBs after 2 years (26%), compared with patients (12%) who did not have CMBs at baseline (p=0.03). However, there has been no study on the progression of CMBs in patients receiving so-called novel oral anticoagulants (NOACs).

    NOACs, including dabigatran (Hart et al, Stroke 2012), rivaroxaban (Patel et al, N Engl J Med 2011), apixaban (Granger CB et al, N Engl J Med 2011), and edoxaban (Giugliano et al, N Engl J Med 2013), are superior to warfarin in preventing stroke or systemic embolism in patients with NVAF, and have been reported to significantly reduce the incidence of hemorrhagic stroke. Therefore, this study was designed to evaluate and compare the absolute number of CMBs in patients with at least one CMB at baseline, who receive anticoagulant therapy with NOACs and with warfarin. The correlation between CMBs and intracranial hemorrhage, as well as the status of CMBs before commencement of treatment and their progression during treatment, will be evaluated to determine whether there are differences between the two groups.

  2. The feature of this study Japan has a very high availability of MRI facilities, and thus CMBs can be readily evaluated in multiple patients using T2*WI. As of January 1, 2013, the total population of Kanagawa Prefecture was 9.07 million, of whom the elderly (≥65 years) comprised 1.95 million; therefore, a clinical observational study covering this prefecture that revealed a significant difference between NOACs and warfarin should have a substantial impact on drug-prescribing practice.

    CMBs found on T2*-weighted gradient-echo MRI 1.5 Tesla should be evaluated. The imaging data will be evaluated by the Cerebral Microbleeds Evaluation Committee using the assessment scale of Gregoire et al. under a blinded condition.

  3. Study design This study tests the hypothesis that the incidence of hemorrhagic stroke is lower in patients receiving NOACs than in those receiving warfarin, and this difference reflects the difference in the effects of warfarin and NOACs on the progression of CMBs in patients with at least one CMB.

    This study is an observational study, and the numbers of patients in the NOACs and warfarin groups were not predetermined, though the total number of patients for the study was limited to 200 for practical reasons. Primary endpoint is the proportion of subjects with an increased number of CMBs at Month 12 of treatment with NOACs or warfarin. If the results of this study support the efficacy of NOACs in preventing increase of CMBs, this would be of great interest to domestic and overseas clinicians, in view of the potential therapeutic impact, including that for primary prevention of ischemic stroke.

    For quality assurance, data validation and registry procedures including any plans for site monitoring and auditing is performed.

  4. Sample Size and Sample Size Justification Orken et al. (Clin Neurol Neurosurg, 2013) suggested that more patients who had CMBs at baseline developed new CMBs (26%) after 2 years, compared with patients (12%) who did not have CMBs at baseline. Therefore, the rate of new CMBs in warfarin-treated patients who had at least one CMB at baseline was assumed to be 13% in 1-year follow-up. Meanwhile, in the ENGAGE AF-TIMI study, the incidence of intracranial hemorrhage among patients receiving edoxaban (one of the NOACs) was about half of that in patients receiving warfarin; the rate of appearance of new CMBs was assumed to be 6.5%. Simulations (10,000 times) indicated that the probability that the rank order of the rate of newly developed CMBs in 1 year would not be reversed between the two groups was 92.7% (power: 19%, two-sided α= 0.05). As this is a pilot study, the number of necessary subjects was estimated to be 100 subjects in 1 group and 200 in 2 groups combined, based on the above results.
  5. Statistical Analysis plan For proportion with new CMBs at month 6 and at month 12, number of new CMBs at months 6 and 12, and location of CMBs, major analyses will be conducted according to the per protocol set (PPS) principle. In addition, for incidence rate of adverse events, major analyses will be conducted according to the intention to treat (ITT) principle. As the primary endpoints analyses (proportion with new CMBs at month 12), the NOACs group and the warfarin group will be compared with respect to total CMBs positive proportion. It' will be also compared between the NOACs group and the warfarin group about the respective secondary endpoints (proportion with new CMBs at month 6, number of new CMBs at months 6 and 12, location of CMBs, incidence rate of adverse events). Proportion of subjects with an increased number of CMBs at month 12 is compared among NOACs. As the need arises, such as the comparison among NOACs, it will be stratified by the factors which are a patient background, the treatment contents and etc., and will be analyzed.
03

Conditions studied

  • Ischemic Stroke
  • Atrial Fibrillation Symptomatic

Browse trials for

Keywords

  • non-valvular atrial fibrillation
  • cerebral microbleeds
  • warfarin
  • NOACs
  • acute ischemic stroke
04

Who can participate

Ages eligible
20 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with NVAF, who had at least one CMB at the time of entry into this study, and were prescribed a NOAC (dabigatran, rivaroxaban, apixaban, or edoxaban) or warfarin for secondary prevention of cerebral infarction or transient ischemic attack within 2 weeks after the onset. This study is an observational study, and the numbers of patients in the NOACs and warfarin groups were not predetermined, though the total number of patients for the study was limited to 200 for practical reasons.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of NVAF
  2. Diagnosis of cerebral infarction or within 2 weeks after onset
  3. Patients commenced on NOACs or warfarin therapy as a secondary prevention of cerebral infarction or transient ischemic attack, whether or not anticoagulation therapy was used before enrollment in this study
  4. Age ≥20 years and ≤85 years
  5. Ability to give valid consent and to provide consent in writing or availability of relatives to provide surrogate consent.
  6. At least one CMB detected by 1.5 T MRI (T2*WI) before enrollment in this study

Exclusion criteria

Exclusion Criteria:

  1. Patients using aspirin or other antiplatelet agents concomitantly
  2. Patients in whom NOAC or warfarin is
  3. Patients with renal dysfunction (CrCL \<15 mL/min)
  4. Patients with uncontrollable hypertension
  5. Patients who are otherwise ineligible to take part in this study as judged by the study doctor
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
86 participants (actual)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • NOACs group

    Medication with dabigatran, rivaroxaban, apixaban, or edoxaban will not be assigned, but will be freely prescribed by each attending doctor based on assessment of the condition of each patient.

  • Warfarin group

    Medication with warfarin: PT-INR should be controlled in accordance with the JCS2008 guideline concerning the drug treatment of atrial fibrillation, that is, INR 2.0 to 3.0 in patients younger than 70 years, or INR 1.6 to 2.6 in patients not younger than 70 years.

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with an increased number of CMBs at Month 12 of treatment with NOACs or warfarin

    Time frame: 1 year

Secondary outcomes

  1. Proportion of subjects with an increased number of CMBs at Month 6 of treatment with NOACs or warfarin

    Time frame: 6 months

  2. The number of new CMBs in subjects with an increased number of CMBs at Months 6 and 12 of treatment with NOACs or warfarin

    Time frame: 1 year

  3. Location of CMBs (infratentorial, deep white matter, and lobar subgroups) in the NOACs and warfarin groups

    Time frame: 1 year

  4. Incidence rate of adverse events

    Incidence rate of ischemic events (cerebral infarction, non-CNS embolism, myocardial infarction, etc.), hemorrhagic events (symptomatic intracranial hemorrhage, subarachnoidal hemorrhage, subdural hematoma, subdural hematoma, etc.), and other adverse events

    Time frame: 1 year

07

Study locations

3 sites
  • St. Marianna University School of Medicine Hospital
    Kawasaki, Kanagawa 216-8511, Japan
  • Kitasato University Hospital
    Sagamihara, Kanagawa 252-0373, Japan
  • Yokohama City University Hospital
    Yokohama, Kanagawa 236-0004, Japan
08

References and documents

Publications

  • Takizawa S, Tanaka F, Nishiyama K, Hasegawa Y, Nagata E, Mizuma A, Yutani S, Nakayama T, Kobayashi H, Yanagimachi N, Okazaki T, Kitagawa K; CMB-NOW Study Investigators. Protocol for Cerebral Microbleeds during the Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin Therapy in Stroke Patients with Nonvalvular Atrial Fibrillation (CMB-NOW) Study: Multisite Pilot Trial. J Stroke Cerebrovasc Dis. 2015 Sep;24(9):2143-8. doi: 10.1016/j.jstrokecerebrovasdis.2015.05.032. Epub 2015 Jul 4. PubMed 26153510 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2015, a primary completion of Sep 2016 and a completion of Sep 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2015
First posted
Feb 5, 2015
Start
Mar 2015
Primary completionActual
Sep 2016
CompletionEst.
Sep 2017
Last update
Oct 20, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02356432
Lead sponsor
Tokai University
Collaborators
Daiichi Sankyo
Responsible party
Shunya Takizawa, MD, PhD (Professor, Division of Neurology, Department of Internal Medicine, Tokai University School of Medicine, Tokai University) — Principal investigator
First posted
Feb 5, 2015
Start date
Mar 2015
Primary completion
Sep 2016
Completion
Sep 2017 (estimated)
Last update
Oct 20, 2016

Study contacts

Shunya Takizawa, MD, PhD
principal investigator · Tokai University School of Medicine

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion